help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcus, R.
Right arrow Articles by Stock, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcus, R.
Right arrow Articles by Stock, J. L.
Endocrine Reviews 23 (1): 16-37
Copyright © 2002 by The Endocrine Society

Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint

Robert Marcus, Mayme Wong, Hunter Heath, III and John L. Stock

Department of Medicine, Stanford University School of Medicine, and the Musculoskeletal Research Laboratory, Geriatric Research, Education, and Clinical Center, Veterans’ Affairs Medical Center (R.M.), Palo Alto, California 94304; and Lilly Research Laboratories, Eli Lilly and Company (M.W., H.H.III, J.L.S.), Indianapolis, Indiana 46285

Correspondence: Address all correspondence and requests for reprints to: Robert Marcus, M.D., Professor of Medicine, Stanford University, Geriatric Research, Education, and Clinical Center 182-B, Veterans’ Affairs Medical Center, 3801 Miranda Avenue, Palo Alto, California 94304. E-mail: marcuse{at}Stanford.edu

Antiresorptive treatments for postmenopausal osteoporosis have been studied extensively, but due to the volume of published data and lack of head-to-head trials, it is difficult to evaluate and compare their fracture reduction efficacy. The objective of this review is to summarize the results from clinical trials that have fracture as an endpoint and to discuss the factors in study design and populations that can affect the interpretation of the results. Although there are numerous observational studies suggesting that estrogen and hormone replacement therapies may reduce the risk of vertebral and nonvertebral fractures, there is no large, prospective, randomized, placebo-controlled, double-blind clinical trial demonstrating fracture efficacy. The effects of raloxifene, alendronate, risedronate, and salmon calcitonin on increasing bone mineral density (BMD) and decreasing fracture risk have been shown in randomized, placebo-controlled, double-blind clinical trials of postmenopausal women with osteoporosis. Although the increases in lumbar spine BMD vary greatly in these trials, the decrease in relative risk of vertebral fractures is similar among therapies. However, nonvertebral fracture efficacy has not been consistently demonstrated. Combined administration of two antiresorptive therapies results in greater BMD increases, but the effects on fracture risk are unknown. Direct comparisons of clinical trial results should be considered carefully, given the differences in study design and populations. Differences in study design that may influence the efficacy of fracture risk reduction include calcium and vitamin D supplementation, primary fracture endpoints, definition of vertebral deformity or fracture, discontinuation rates, and statistical power. Factors in the study population that may influence fracture efficacy include the age of the population and the proportion of subjects with prevalent fractures. The use of surrogate endpoints such as BMD to predict fracture risk should be approached with caution, as the relationship between BMD changes and fracture risk reduction with antiresorptive therapies is uncertain. Consideration of these results from clinical trials can contribute to clinical judgment in selecting the best treatment option for postmenopausal osteoporosis.




This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
K. A. Hegge, A. S. Fornoff, S. L. Gutierres, and S. L. Haack
New Therapies for Osteoporosis
Journal of Pharmacy Practice, February 1, 2009; 22(1): 53 - 64.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Tauchmanova, A. Colao, G. Lombardi, B. Rotoli, and C. Selleri
REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4536 - 4545.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
F. Jakob, F. Marin, E. Martin-Mola, D. Torgerson, P. Fardellone, S. Adami, N.C. Thalassinos, D. Sykes, J. Melo-Gomes, C. Chinn, et al.
Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)
QJM, August 1, 2006; 99(8): 531 - 543.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
K. F. Mauck and B. L. Clarke
Diagnosis, Screening, Prevention, and Treatment of Osteoporosis
Mayo Clin. Proc., May 1, 2006; 81(5): 662 - 672.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Tauchmanova, P. Ricci, B. Serio, G. Lombardi, A. Colao, B. Rotoli, and C. Selleri
Short-Term Zoledronic Acid Treatment Increases Bone Mineral Density and Marrow Clonogenic Fibroblast Progenitors after Allogeneic Stem Cell Transplantation
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 627 - 634.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
G. J. Strewler
Long-Term Bisphosphonates for Osteoporosis: An Introduction
IBMS BoneKEy, January 1, 2005; 2(1): 6 - 9.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. L. Becker, E. S. Nylen, J. C. White, B. Muller, and R. H. Snider Jr.
Procalcitonin and the Calcitonin Gene Family of Peptides in Inflammation, Infection, and Sepsis: A Journey from Calcitonin Back to Its Precursors
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1512 - 1525.
[Full Text] [PDF]


Home page
Hum ReprodHome page
M. Doren, J.-A. Nilsson, and O. Johnell
Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis
Hum. Reprod., August 1, 2003; 18(8): 1737 - 1746.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society